Clinical Trial Update: Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense [Phase 2]

View source ↗

Summary

Phase II trial of subcutaneous immunotherapy for patients with allergic rhinoconjunctivitis due to Phleum pratense has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis

Drugs mentioned

• Subcutaneous immunotherapy (unspecified) for Phleum pratense

Snippet

Sponsor: Roxall Medicina España S.A | Conditions: Allergic Rhinoconjunctivitis | Phase 2 | Status: COMPLETED | Results posted: 2019-04-29